Patritumab Deruxtecan Application Withdrawn for EGFR-Mutated Lung Cancer
TL;DR
Merck and Daiichi Sankyo have voluntarily withdrawn their Biologics License Application for patritumab deruxtecan for treating EGFR-mutated non-small cell lung cancer after the Phase 3 trial failed to meet overall survival endpoints, despite promising progression-free survival results.
Topics:businesshealthcare#clinical-trial#egfr-mutation#healthcare#lung-cancer#merck#patritumab-deruxtecan
Want the full story? Read the original reporting
Read on Merck.com